|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
et al: SEER cancer statistics review 1975–2012. Natl Cancer Inst.
Nov 18–2015.
|
|
3
|
Iranzo V, Bremnes RM, Almendros P, Gavilá
J, Blasco A, Sirera R and Camps C: Induction chemotherapy followed
by concurrent chemoradiation for patients with non-operable stage
III non-small-cell lung cancer. Lung Cancer. 63:63–67. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ozkaya S, Findik S, Dirican A and Atici
AG: Long-term survival rates of patients with stage IIIB and IV
non-small cell lung cancer treated with cisplatin plus vinorelbine
or gemcitabine. Exp Ther Med. 4:1035–1038. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomized, phase 3 study.
Lancet oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomized phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Russmann S, Kullak-Ublick GA and
Grattagliano I: Current concepts of mechanisms in drug-induced
hepatotoxicity. Curr Med Chem. 16:3041–3053. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Leanza L, Henry B, Sassi N, Zoratti M,
Chandy KG, Gulbins E and Szabò I: Inhibitors of mitochondrial Kv1.
3 channels induce Bax/Bak-independent death of cancer cells. EMBO
Mol Med. 4:577–593. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Russmann S, Jetter A and Kullak-Ublick GA:
Pharmacogenetics of drug-induced liver injury. Hepatology.
52:748–761. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Teo YL, Ho HK and Chan A: Risk of tyrosine
kinase inhibitors-induced hepatotoxicity in cancer patients: A
meta-analysis. Cancer Treat Rev. 39:199–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao S, Li H, Jiang C, Ma T, Wu C, Huo Q
and Liu H: 17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces
mitochondria-mediated apoptosis through downregulation of Mcl-1 in
human hepatocellular carcinoma cells. J Bioenerg Biomembr.
47:373–381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Zhou ZW, Jin H, Hu C, He ZX, Yu
ZL, Ko KM, Yang T, Zhang X, Pan SY and Zhou SF: Schisandrin B
inhibits cell growth and induces cellular apoptosis and autophagy
in mouse hepatocytes and macrophages: Implications for its
hepatotoxicity. Drug Des Devel Ther. 9:2001–2027. 2015.PubMed/NCBI
|
|
13
|
Chen L, Zhang F, Kong D, Zhu X, Chen W,
Wang A and Zheng S: Saikosaponin D disrupts platelet-derived growth
factor-β receptor/p38 pathway leading to mitochondrial apoptosis in
human LO2 hepatocyte cells: A potential mechanism of
hepatotoxicity. Chem Biol Interact. 206:76–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oliver FJ, de la Rubia G, Rolli V,
Ruiz-Ruiz MC, de Murcia G and Murcia JM: Importance of
poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson
from an uncleavable mutant. J Biol Chem. 273:33533–33539. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaiser WJ, Upton JW, Long AB,
Livingston-Rosanoff D, Daley-Bauer LP, Hakem R, Caspary T and
Mocarski ES: RIP3 mediates the embryonic lethality of
caspase-8-deficient mice. Nature. 471:368–372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guha M, Maity P, Choubey V, Mitra K,
Reiter RJ and Bandyopadhyay U: Melatonin inhibits free
radical-mediated mitochondrial-dependent hepatocyte apoptosis and
liver damage induced during malarial infection. J Pineal Res.
43:372–381. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang F, Chen L, Jin H, Shao J, Wu L, Lu Y
and Zheng S: Activation of Fas death receptor pathway and Bid in
hepatocytes is involved in saikosaponin D induction of
hepatotoxicity. Environ Toxicol Pharmacol. 41:8–13. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee WM: Etiologies of acute liver failure.
Semin Liver Dis. 28:142–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McGill MR and Jaeschke H: Mechanistic
biomarkers in acetaminophen-induced hepatotoxicity and acute liver
failure: From preclinical models to patients. Expert Opin Drug
Metab Toxicol. 10:1005–1017. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Williams CD, McGill MR, Farhood A and
Jaeschke H: Fas receptor-deficient lpr mice are protected against
acetaminophen hepatotoxicity due to higher glutathione synthesis
and enhanced detoxification of oxidant stress. Food Chem Toxicol.
58:228–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McGill MR, Sharpe MR, Williams CD, Taha M,
Curry SC and Jaeschke H: The mechanism underlying
acetaminophen-induced hepatotoxicity in humans and mice involves
mitochondrial damage and nuclear DNA fragmentation. J Clin Invest.
122:1574–1583. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu J, Ramshesh VK, McGill MR, Jaeschke H
and Lemasters JJ: Low dose acetaminophen induces reversible
mitochondrial dysfunction associated with transient c-Jun
N-terminal kinase activation in mouse liver. Toxicol Sci.
150:204–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen X, Yang S and Ma S: Drug induced
hepatotoxicity in targeted therapy for lung cancer. Zhongguo Fei Ai
Za Zhi. 17:685–688. 2014.(In Chinese). PubMed/NCBI
|
|
24
|
Xue T, Luo P, Zhu H, Zhao Y, Wu H, Gai R,
Wu Y, Yang B, Yang X and He Q: Oxidative stress is involved in
Dasatinib-induced apoptosis in rat primary hepatocytes. Toxicol
Appl Pharmacol. 261:280–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang X, Wang J, Dai J, Shao J, Ma J, Chen
C, Ma S, He Q, Luo P and Yang B: Autophagy protects against
dasatinib-induced hepatotoxicity via p38 signaling. Oncotarget.
6:6203–6217. 2015. View Article : Google Scholar : PubMed/NCBI
|
